Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based […]
Archive for the
‘2020’ Category
Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director Ghent, Belgium – June 10, 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and […]
Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer –New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– Ghent, Belgium – June 3, 2020 – Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective […]
Confo Therapeutics to present at Cowen 40th Annual Health Care Conference Ghent, Belgium, 27 February 2020 – Confo Therapeutics, a pioneering biopharma company, today announces that Cedric Ververken, CEO, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 3:00 p.m. ET in Boston, MA. Confo Therapeutics is also […]